Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Inflammatory Disease, and Cancer Stem Cell Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LIFR/CD118 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LIFR ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View LIFR Products |
| Gene Delivery | LIFR Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction (Ba/F3 or HEK293). | View LIFR Products |
| Benchmark Ab | Anti-LIFR Reference Antibody. Recombinant monoclonal for assay calibration and positive control. | View LIFR Products |
| Validator | LIFR siRNA Set (3 unique targets). For knockdown specificity verification. | View LIFR Products |
| Related Target A | LIF (Leukemia Inhibitory Factor). Primary ligand; required for competitive binding assays. | View LIF Products |
| Related Target B | IL6ST (gp130). Obligatory co-receptor for functional LIFR signaling complex. | View IL6ST Products |
| Related Target C | OSMR (Oncostatin M Receptor). Shares gp130; critical for selectivity screening vs. OSMR subfamily. | View OSMR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand/Receptor Complex Formation (LIF/LIFR/gp130) | Native glycosylation via HEK293 expression ensures proper folding; co-expression lentivirus available for cell-based assays. |
| Ligand Competition & Blocking Efficacy | High-purity LIFR ECD-Fc (Theoretical MW ~110 kDa glycosylated) for SPR/BLI kinetics. |
| Cross-species Preclinical Evaluation | Human, Cynomolgus, and Mouse LIFR ortholog proteins available with >95% purity and sequence verification. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| Target Specificity vs. OSMR Subfamily | Homolog panel (OSMR, IL6ST, LIFR) strictly verified by mass spec to rule out off-target binding. |
Live LIFR/CD118 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LIFR/CD118 therapeutics is intensifying, with major players shifting focus from traditional inflammatory indications to tumor microenvironment (TME) modulation in solid tumors. The LIFR/CD118 axis is emerging as a critical regulator of cancer stemness and therapy resistance. While initial development focused on ligand neutralization (anti-LIF antibodies such as MSC-1/AZD0171), the field is pivoting toward receptor-targeted strategies to disrupt the LIF-LIFR-gp130 ternary complex with greater specificity. Current R&D emphasizes ADC constructs for LIFR-positive solid tumors and bispecific formats targeting both LIFR and tumor-associated antigens. As first-generation therapies validate the pathway, the next wave targets combination strategies with immune checkpoint inhibitors and chemotherapy to overcome resistance mechanisms driven by IL-6 family cytokines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | AstraZeneca, Northern Biologics, Novartis, Astellas | Pancreatic Cancer, Solid Tumors, Fibrosis | Blocking Assay: high-purity ECD-Fc & Ligand; Heterodimer competition requires LIFR+gp130 co-expression. |
| Bispecific Antibody | Early-stage Biotechs | Advanced Solid Tumors, Cancer Immunotherapy | Heterodimer validation; cross-reactivity panel (LIFR vs OSMR) essential. |
| ADC | Emerging biotech, Academic | Pancreatic, Breast Cancer | Internalization assay: high-purity ECD-Fc for uptake quantification; fluorescent conjugates. |
| Small Molecule | Academic/Spin-offs | Breast Cancer, Melanoma | Selectivity assay: structural conformation & high purity; cell-based STAT3 phosphorylation assay. |
| Decoy Receptor | Preclinical | Inflammatory Diseases | Ligand binding affinity: high-avidity LIFR ECD for potency testing. |